Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial
Introduction: Cardiovascular diseases have become the leading cause of death around the globe and diabetes mellitus (DM) is considered to be a coronary artery disease (CAD) risk equivalent. Ranolazine, an anti anginal drug has been found to reduce Glycated haemoglobin (HbA1c) in diabetes patient...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-01-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5448/10594_CE(RA1)_F(T)_PF1(NJAK)_PF2(PAK)_PFA(AK)_PF2(PAG).pdf |
| Summary: | Introduction: Cardiovascular diseases have become the leading
cause of death around the globe and diabetes mellitus (DM) is
considered to be a coronary artery disease (CAD) risk equivalent.
Ranolazine, an anti anginal drug has been found to reduce Glycated
haemoglobin (HbA1c) in diabetes patients with chronic angina.
However the effect of another antianginal drug trimetazidine, on
glycemic status is not clear.
Aim: To compare the effect of ranolazine and trimetazidine on
glycemic status in diabetic patients with CAD.
Settings and Design: Patients diagnosed with CAD and
diabetes mellitus attending Cardiology Out Patient Department
(OPD), Jawaharlal Institute of Postgraduate Medical Education
& Research (JIPMER), Puducherry, India were recruited for this
randomized open label parallel arm trial.
Materials and Methods: The study conducted from January2012 to April-2013 had 47 eligible patients diagnosed with CAD
and diabetes mellitus. They were randomized to receive either
ranolazine 500 mg BD or trimetazidine 35 mg BD for 12 weeks.
HbA1c levels, fasting blood glucose (FBG), lipid profile, QT and QTc
intervals were measured at baseline and after 12 weeks.
Statistical Analysis: Unpaired t-test was used to compare the
baseline characteristics of between the groups while comparison
within the groups were done using Paired t-test. Wilcoxon and Mann
Whitney U-tests were used for non parametric data. Graph pad instat
version-3 was used for statistical analysis. Values were expressed as
mean ± SD. A p < 0.05 was considered statistically significant.
Results: The study could not find any change in HbA1c levels in
both ranolazine and trimetazidine groups. The adverse effects
reported from patients on ranolazine include angina, constipation,
postural hypotension, headache, dizziness, nausea and weakness
while patients on trimetazidine complained of constipation,
weakness, palpitations, angina, dizziness, nausea, dyspepsia,
headache, gastric discomfort, joint pain, etc.
Conclusion: In patients with chronic angina and diabetes mellitus
Ranolazine 500mg BD and Trimetazidine 35mg BD did not show
any effect on HbA1c and fasting blood glucose lebel. |
|---|---|
| ISSN: | 2249-782X 0973-709X |